People searching for GLP-3 are often looking for information about dual agonists, triple agonists, GLP-2, or investigational medications such as retatrutide
Drawing from published clinical data, mechanism-of-action research, and the emerging body of real-world observations, this is the most comprehensive timeline available for understanding retatrutide results from first injection to peak efficacy
For anything higher, you would need to either switch to a 1mL syringe or draw two separate injections
staying active keeps your glutathione levels steady over time
However, liraglutide and other GLP-1 medications currently face shortages
Some aspects of the research appear promising, while others remain unproven: What appears promising so far: Reduced substance-seeking behavior observed in animal models Anecdotal and observational reports of decreased cravings in some individuals Growing scientific interest in shared reward pathways between appetite and addiction What remains unproven or unclear: Whether observed effects lead to sustained recovery outcomes How GLP-1s affect the psychological and social dimensions of addiction Whether benefits, if present, are consistent across substances or populations Differences in study design also limit interpretation: Animal trials do not reliably predict human outcomes Observational data cannot establish causation Controlled human trials remain small, limited, and inconsistent Safety considerations are equally important and must be weighed carefully: Common side effects include nausea, appetite suppression, and gastrointestinal distress Changes in appetite or weight may interact with existing mental health symptoms For individuals with eating disorders, appetite-suppressing effects may pose particular risks Given these uncertainties, GLP-1 medications should not replace evidence-based addiction treatments
